IPG0521 / Immunophage Biotech - LARVOL DELTA

Development of a CCR8 monoclonal antibody to block CCR8 signaling and to abolish the immunosuppressive function of Treg for the treatment of cancers. (ASCO 2023) - "IPG0521 has potent anti-tumor effects in multiple tumor types, including lung, liver, and breast cancers, in both syngeneic and immune-humanized mouse models. It inhibits Tregs immunosuppression and activates CD8+ T cells to achieve its anti-tumor effects. These results support the development of IPG0521, which is currently under IND filing, as a novel therapeutic agent for the treatment of cancers."

Breast Cancer • Oncology • Solid Tumor • CCR8 • CD8 • PTPRC

Development of a CCR8 monoclonal antibody which blocks CCR8 signaling and abolishes the immunosuppressive function of Treg for the treatment of cancer (AACR 2023) - "IPG0521 potently inhibited the growth of multiple tumor types in both syngeinic and immune-humanized mouse models, including lung cancer, liver cancer, breast cancer, via inhibiting Treg and activating CD8+ T cells. These data pave the way for the development of IPG0521, which is under IND filing, as a novel therapeutic agent against cancer."

Breast Cancer • Gastrointestinal Cancer • Liver Cancer • Lung Cancer • Oncology • Solid Tumor • CCR8 • CD8 • CTLA4 • IL10 • PD-1 • TIGIT

Development of a CCR8 monoclonal antibody for the treatment of cancer (ESMO 2022) - "Conclusions Based on these pre-clinical data IPG0521, a highly selective CCR8 antagonist, is being developed for the selective inhibition of tumor-infiltrating Tregs. IPG0521 may be useful in PD-1 resistant settings and may restore the activity of PD-1 inhibitors in the setting of primary or acquired resistance to immune checkpoint blockers."

Breast Cancer • Gastrointestinal Cancer • Liver Cancer • Lung Cancer • Oncology • Solid Tumor • CCR8 • CD8